Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.
Jonathan M. Gerber, MD
Advertisement
Jonathan M. Gerber, MD, is a member of the faculty in the Department of Medicine at New York University (NYU) Grossman School of Medicine; as well as the chief clinical officer of the NYU Perlmutter Cancer Center.
Articles by Jonathan M. Gerber, MD
Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.
Advertisement
Latest Updated Articles
IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhDPublished: July 16th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5